Lung Cancer Diagnostics Market (2026 - 2036)

Lung Cancer Diagnostics Market size, market forecast and outlook by FMI

The lung cancer diagnostics market was valued at USD 13.30 billion in 2025, projected to reach USD 14.30 billion in 2026, and is forecast to expand to USD 29.47 billion by 2036 at a 7.50% CAGR. Based on Future Market Insights analysis, the market is set to add an incremental opportunity worth USD 15.17 billion over the forecast period. As per FMI, the procurement landscape for lung cancer diagnostics is being reshaped by evolving specification requirements, regional capacity investments, and shifting end-use demand patterns.

Three forces are expanding the lung cancer diagnostics market beyond its historical imaging and tissue pathology base. First, the molecular diagnostic testing menu is lengthening as each new targeted therapy approval adds a companion diagnostic requirement, and comprehensive genomic profiling panels are replacing sequential single-gene tests to capture all actionable alterations in a single workflow. Second, liquid biopsy technology is maturing from research novelty to clinical standard for EGFR T790M resistance mutation detection and treatment response monitoring, creating a recurring testing revenue model alongside upfront tissue-based diagnosis. Third, AI-assisted CT interpretation software is improving lung nodule detection sensitivity and specificity, increasing the diagnostic yield of screening programs and generating more patients who proceed to confirmatory molecular testing.

Across tracked geographies, China sets the pace at 10.10% CAGR. India follows at 9.40%. Germany follows at 8.60%. France follows at 7.90%. UK follows at 7.10%. USA follows at 6.40%. Brazil follows at 5.60%.

Summary of Lung Cancer Diagnostics Market

• Lung Cancer Diagnostics Market definition
  • The lung cancer diagnostics market encompasses molecular testing platforms, imaging technologies, liquid biopsy assays, and companion diagnostic kits used to detect, classify, and genotype non-small cell and small cell lung cancers, enabling treatment selection through EGFR mutation testing, ALK rearrangement analysis, PD-L1 expression scoring, and comprehensive genomic profiling in laboratory, hospital, and point-of-care settings.
• Demand drivers in the market
  • Targeted therapy and immunotherapy approvals for NSCLC are expanding the menu of required companion diagnostic tests per patient, as each new drug indication requires a corresponding biomarker assay that must be performed before treatment initiation, directly increasing per-patient diagnostic spend.
  • National lung cancer screening programs using low-dose CT are expanding across the United States, Europe, and East Asia, generating a growing pipeline of screen-detected nodules that require follow-up tissue biopsy and molecular characterization to confirm diagnosis and guide treatment.
  • Liquid biopsy adoption for EGFR mutation monitoring and minimal residual disease detection is creating a longitudinal testing revenue stream where each patient may undergo multiple blood-based assays during treatment cycles, supplementing the one-time tissue biopsy diagnostic model.
• Key segments analyzed in the FMI report
  • Non-small cell lung cancer type: 68.7% share in 2026, reflecting established specifications and supply chain infrastructure.
  • EGFR Mutation test test: 40.8% share in 2026, driven by end-use requirements in the primary channels.
  • China: 10.10% compound growth, supported by domestic investment and rising consumption.
• Analyst opinion at FMI
  • The lung cancer diagnostics market is driven by the expanding intersection of biomarker-directed therapy and regulatory companion diagnostic requirements. As per FMI, the companies capturing the largest share of diagnostic spend are those offering comprehensive genomic profiling platforms that consolidate multiple single-gene tests into a single assay, because oncologists and pathology laboratories prefer workflow simplification over sequential testing that delays treatment initiation. The risk for the market is reimbursement: payer coverage policies for comprehensive genomic profiling and liquid biopsy vary across geographies, and any tightening of reimbursement criteria would compress diagnostic utilization rates.
• Strategic implications / executive takeaways
  • Diagnostic companies must expand comprehensive genomic profiling panel content to include emerging biomarkers as new targeted therapies enter late-stage clinical trials, because panel comprehensiveness determines laboratory adoption and oncologist ordering preference.
  • Clinical laboratory directors should evaluate liquid biopsy platforms for EGFR monitoring and minimal residual disease applications to capture the longitudinal testing revenue opportunity that tissue-only diagnostic models cannot serve.
  • Screening program administrators should invest in AI-assisted CT interpretation software to improve nodule detection rates and reduce radiologist reading burden as national screening program enrollment expands.

Lung Cancer Diagnostics Market key takeaways

Metric	Details
Industry Size (2026)	USD 14.30 billion
Industry Value (2036)	USD 29.47 billion
CAGR (2026 to 2036)	7.50%

Source: Future Market Insights, 2026

Lung Cancer Diagnostics Market definition

Lung cancer diagnostics represent the in-vitro diagnostic and imaging technology category used to identify lung malignancies, determine histological subtype, and characterize actionable genomic alterations that guide targeted therapy and immunotherapy treatment decisions. These diagnostics operate across the clinical pathway from screening through treatment monitoring, employing next-generation sequencing, PCR-based assays, immunohistochemistry, and low-dose computed tomography platforms.

Lung Cancer Diagnostics Market inclusions

Market scope includes all commercially traded lung cancer diagnostic products segmented by type (non-small cell lung cancer, small cell lung cancer), test (EGFR mutation test, ALK rearrangement test, PD-L1 expression test, KRAS mutation test, comprehensive genomic profiling), and end use (laboratories, hospitals, academic research centers). Revenue sizing spans the 2026 to 2036 forecast period.

Lung Cancer Diagnostics Market exclusions

The scope excludes lung cancer therapeutic drugs, radiation therapy equipment, surgical instruments, and general-purpose laboratory equipment not specifically configured for lung cancer diagnostic workflows. Screening CT scanners sold without lung cancer-specific AI-assisted detection software are outside the defined boundary.

Lung Cancer Diagnostics Market research methodology

• Primary research: FMI analysts conducted interviews with procurement directors, engineering leads, and product managers across key lung cancer diagnostics organizations to map decision gates and sourcing specifications.
• Desk research: Data collection aggregated regulatory filings, trade association publications, standards body documentation, and company annual reports to establish verifiable baseline parameters.
• Market sizing and forecasting: Baseline values derive from a bottom-up aggregation of lung cancer diagnostics transaction volumes, applying region-specific adoption curves and pricing indices to project demand through 2036.
• Data validation and update cycle: Projections are tested against publicly reported procurement volumes, trade flow statistics, and company financial disclosures on a quarterly refresh schedule.

Why is the Lung Cancer Diagnostics Market Growing?

Market expansion is being supported by the increasing global burden of lung cancer and the corresponding demand for accurate, timely diagnostic solutions. Modern healthcare systems are increasingly focused on early detection strategies that can improve survival rates and treatment outcomes. The shift toward personalized medicine and targeted therapies requires comprehensive molecular characterization of tumors, driving demand for advanced diagnostic technologies, including next-generation sequencing, liquid biopsies, and companion diagnostics.

The growing focus on minimally invasive diagnostic procedures is driving demand for blood-based tests and imaging-guided biopsies that reduce patient discomfort and procedural risks. Healthcare provider’s preference for multiplexed testing platforms that can assess multiple biomarkers simultaneously is creating opportunities for innovative diagnostic solutions. The rising influence of clinical guidelines recommending molecular testing and the increasing availability of targeted therapies are also contributing to increased diagnostic test utilization across different healthcare settings and patient populations.

Segmental Analysis

The market is segmented by type, test, end use, and region. By type, the market is divided into non-small cell lung cancer and small cell lung cancer diagnostics. Based on test, the market is categorized into EGFR mutation tests, HER2 tests, ALK tests, angiogenesis inhibitors, CA tests, and KRAS mutation tests. In terms of end use, the market is segmented into laboratories, hospitals, and others. Regionally, the market is divided into North America, Europe, East Asia, South Asia & Pacific, Latin America, and Middle East & Africa.

By Type, Non-Small Cell Lung Cancer Segment Accounts for 68.9% Market Share

The non-small cell lung cancer (NSCLC) diagnostics segment is projected to account for 68.9% of the lung cancer diagnostics market in 2026, reaffirming its position as the dominant category due to its higher prevalence compared to other lung cancer types. NSCLC represents approximately 85% of all lung cancer cases globally, making it the primary focus for diagnostic development and clinical implementation. The segment benefits from extensive research into actionable mutations and the availability of numerous targeted therapy options that require companion diagnostic testing.

This type forms the foundation of most precision medicine approaches in lung cancer, as it encompasses multiple molecular subtypes with distinct therapeutic implications. The presence of well-characterized driver mutations such as EGFR, ALK, ROS1, and KRAS in NSCLC patients has led to the development of comprehensive molecular profiling panels. Clinical guidelines consistently recommend broad molecular testing for NSCLC patients, ensuring demand and market dominance for this segment across all healthcare settings and geographic regions.

By Test, EGFR Mutation Test Segment Accounts for 40.9% Market Share

EGFR mutation tests are projected to represent 40.9% of lung cancer diagnostics demand in 2026, underscoring their role as the most established and widely adopted molecular diagnostic test in lung cancer management. The test's clinical utility is well-established, with EGFR mutations found in approximately 10-15% of Western populations and up to 50% of Asian populations with lung adenocarcinoma. The availability of multiple FDA-approved targeted therapies for EGFR-mutated tumors has created a strong clinical imperative for testing.

The segment is supported by robust clinical evidence demonstrating improved outcomes with EGFR-targeted therapy in mutation-positive patients compared to conventional chemotherapy. The test's inclusion in major clinical guidelines and reimbursement coverage across developed markets ensures consistent utilization. As resistance mechanisms to first and second-generation EGFR inhibitors become better understood, the demand for comprehensive EGFR mutation analysis, including T790M resistance mutation testing, continues to expand the market opportunity for this dominant diagnostic segment.

By End Use, Laboratories Segment Accounts for 51.6% Market Share

The laboratories segment is forecasted to contribute 51.6% of the lung cancer diagnostics market in 2026, reflecting the centralized nature of molecular diagnostic testing and the specialized expertise required for complex assay interpretation. Clinical laboratories offer standardized testing conditions, quality assurance programs, and the technical infrastructure necessary for high-throughput molecular diagnostics. This centralized model ensures consistent test quality and allows for cost-effective testing at scale.

The segment benefits from ongoing consolidation in the laboratory services industry and the increasing complexity of lung cancer molecular profiling, which requires specialized equipment and trained personnel. Reference laboratories and hospital-based molecular pathology departments serve as centers of excellence for lung cancer diagnostics, offering comprehensive testing menus that include both single-gene assays and large panel sequencing. The laboratory setting also facilitates the integration of artificial intelligence and digital pathology tools that enhance diagnostic accuracy and workflow efficiency.

What are the Drivers, Restraints, and Key Trends of the Lung Cancer Diagnostics Market?

The lung cancer diagnostics market is advancing rapidly due to increasing cancer incidence rates, growing adoption of precision medicine approaches, and expanding availability of targeted therapies. The market faces challenges, including high test costs, reimbursement limitations in emerging markets, and tissue adequacy issues for comprehensive molecular profiling. Innovation in liquid biopsy technologies and artificial intelligence integration continues to influence product development and market expansion patterns.

Expansion of Liquid Biopsy and Circulating Tumor DNA Analysis

The growing adoption of liquid biopsy platforms is enabling non-invasive molecular profiling of lung cancers and providing solutions for patients with limited tissue availability. Blood-based testing offers advantages including reduced procedural risks, ability to monitor treatment response, and detection of emerging resistance mutations. Clinical validation studies and regulatory approvals for liquid biopsy assays are driving adoption across different stages of lung cancer management from initial diagnosis through treatment monitoring.

Integration of Artificial Intelligence and Digital Pathology

Modern lung cancer diagnostic platforms are incorporating artificial intelligence algorithms to enhance image analysis, pattern recognition, and diagnostic interpretation. AI-powered systems improve consistency in pathological assessment, reduce interpretation time, and enable automated biomarker scoring. These technologies also facilitate remote consultation and second opinion services, expanding access to specialized expertise in underserved regions while maintaining diagnostic quality standards.

Analysis of Lung Cancer Diagnostics Market by Key Country

Countries	CAGR (2026-2036)
India	9.4%
China	10.1%
Germany	8.6%
France	7.9%
UK	7.1%
USA	6.4%
Brazil	5.6%

The lung cancer diagnostics market is experiencing robust growth globally, with China leading at a 10.1% CAGR through 2036, driven by large patient population, expanding healthcare infrastructure, and government support for precision medicine initiatives. India follows closely at 9.4%, supported by rising cancer awareness, growing diagnostic capabilities, and increasing healthcare investment. Germany shows steady growth at 8.6%, emphasizing advanced molecular diagnostics and comprehensive testing protocols. France records 7.9%, focusing on innovative diagnostic technologies and research collaboration. The UK demonstrates 7.1% growth, prioritizing early detection programs and precision medicine adoption.

The report covers an in-depth analysis of 40+ countries; seven top-performing countries are highlighted below.

Future Opportunities of Lung Cancer Diagnostics Market in China

Revenue from lung cancer diagnostics in China is projected to exhibit strong growth with a CAGR of 10.1% through 2036, driven by the world's largest lung cancer patient population and rapidly expanding molecular diagnostic capabilities. The country's significant investment in healthcare infrastructure modernization and cancer screening programs is creating substantial demand for advanced diagnostic technologies. Major international and domestic companies are establishing comprehensive testing networks to serve the growing population requiring precision medicine approaches.

• Government initiatives supporting precision medicine development and molecular diagnostic adoption are driving demand for certified and standardized testing platforms throughout major medical centers.
• Healthcare system digitization and artificial intelligence integration are supporting rapid diagnostic workflow optimization and quality improvement across national cancer centers.

In-depth Analysis of Lung Cancer Diagnostics Market in India

Revenue from lung cancer diagnostics in India is expanding at a CAGR of 9.4%, supported by increasing cancer awareness, growing healthcare expenditure, and rising adoption of molecular diagnostic technologies. The country's expanding middle class and increasing exposure to international healthcare standards are driving demand for comprehensive lung cancer molecular profiling. International diagnostic companies and domestic manufacturers are establishing testing facilities to serve the growing demand for precision medicine solutions.

• Rising awareness about targeted therapy benefits and molecular testing is creating opportunities for specialized diagnostic services across urban and metropolitan markets.
• Growing network of cancer specialty hospitals and diagnostic laboratories is driving technology adoption and professional training programs for advanced molecular diagnostics.

Sales Analysis of Lung Cancer Diagnostics in United States

Demand for lung cancer diagnostics in the USA is projected to grow at a CAGR of 6.4%, supported by mature healthcare infrastructure, comprehensive reimbursement coverage, and strong focus on precision medicine implementation. American healthcare systems are increasingly focused on comprehensive molecular profiling, liquid biopsy adoption, and artificial intelligence integration. The market is characterized by strong demand for innovative technologies that improve diagnostic accuracy and clinical decision-making.

• Clinical guideline evolution and professional society recommendations are driving demand for expanded molecular testing panels and next-generation sequencing platforms throughout cancer centers.
• Medicare and private insurance coverage expansion for molecular diagnostics is supporting patient access and utilization across diverse geographic and demographic populations.

Demand Outlook on Lung Cancer Diagnostics in Germany

Revenue from lung cancer diagnostics in Germany is projected to grow at a CAGR of 8.6% through 2036, driven by the country's strong focus on clinical research, advanced healthcare technology adoption, and comprehensive cancer care delivery. German healthcare systems consistently demand high-quality, evidence-based diagnostic solutions that demonstrate clinical utility and cost-effectiveness.

• Ongoing investment in molecular pathology infrastructure and professional training is supporting next-generation diagnostic platform adoption and quality assurance programs.
• Collaboration between academic medical centers and diagnostic companies is enhancing technology development, reinforcing Germany's position as a leader in precision medicine implementation.

Opportunity Analysis of Lung Cancer Diagnostics in the United Kingdom

Revenue from lung cancer diagnostics in the UK is projected to grow at a CAGR of 7.1% through 2036, supported by NHS strategic initiatives promoting early detection and precision medicine adoption. British healthcare policy emphasizes cost-effective diagnostic strategies and evidence-based technology assessment, positioning advanced molecular diagnostics as essential components of comprehensive cancer care.

• National cancer screening programs and molecular diagnostic standardization are increasing accessibility of lung cancer testing across diverse patient populations and geographic regions.
• Public-private partnerships and health technology assessment programs are encouraging diagnostic innovation while ensuring equitable access to precision medicine technologies.

Demand Analysis for Lung Cancer Diagnostics in France

Revenue from lung cancer diagnostics in France is projected to grow at a CAGR of 7.9% through 2036, supported by the country's strong focus on clinical research, technology innovation, and comprehensive cancer care networks. French healthcare systems prioritize evidence-based diagnostic approaches and maintain leadership in molecular pathology and precision medicine development.

• National cancer institutes and research organizations are driving advanced diagnostic technology development and clinical validation studies for lung cancer molecular profiling.
• Comprehensive cancer care networks and specialized diagnostic laboratories are enhancing service delivery while maintaining high standards for diagnostic quality and clinical interpretation.

Growth Outlook on Lung Cancer Diagnostics in Brazil

Revenue from lung cancer diagnostics in Brazil is projected to grow at a CAGR of 5.6% through 2036, supported by healthcare system modernization, increasing cancer awareness, and growing adoption of molecular diagnostic technologies. The country's expanding economy and healthcare investment are creating opportunities for advanced diagnostic service expansion across major metropolitan areas.

• Public and private healthcare sector collaboration is supporting molecular diagnostic infrastructure development and professional training programs for precision medicine implementation.
• International technology partnerships and local manufacturing initiatives are enhancing diagnostic accessibility while reducing costs for comprehensive molecular profiling services.

Europe Market Split by Country

The European lung cancer diagnostics market demonstrates sophisticated development across major economies with Germany leading through its precision molecular diagnostics excellence and advanced clinical research capabilities, supported by companies emphasizing comprehensive genomic profiling platforms, next-generation sequencing technologies, and integrated precision medicine solutions while maintaining strict quality standards and regulatory compliance protocols. The UK shows strength in national healthcare integration and evidence-based diagnostic approaches, with organizations specializing in standardized molecular testing programs and cost-effective precision medicine implementation that meet rigorous clinical standards.

France contributes through its clinical research excellence and comprehensive cancer care networks, delivering advanced diagnostic solutions that combine molecular pathology expertise with modern precision medicine technologies. Sweden and Nordic countries emphasize innovative diagnostic technologies and patient-centered healthcare approaches. Italy and Spain demonstrate growth in specialized molecular diagnostics applications and cancer care infrastructure modernization. The market benefits from stringent EU medical device regulations, established clinical research infrastructure, and growing demand for comprehensive molecular profiling that provides superior therapeutic guidance and patient outcomes.

Japan Market Split by Country

The Japanese lung cancer diagnostics market demonstrates steady growth driven by precision healthcare focus, advanced molecular technology development, and healthcare system preference for high-quality diagnostic solutions that ensure superior accuracy and clinical utility throughout cancer care management. Japanese organizations prioritize sophisticated molecular profiling capabilities and comprehensive quality assurance systems, creating demand for lung cancer diagnostics featuring advanced genomic analysis, liquid biopsy technologies, and integrated artificial intelligence platforms that align with Japanese precision medicine standards.

The market emphasizes technological innovation in molecular diagnostics, biomarker discovery, and personalized treatment approaches that reflect Japanese attention to detail in clinical care delivery and patient outcome optimization. Growing investment in aging population healthcare solutions and cancer care modernization supports adoption of next-generation diagnostic platforms with comprehensive genomic profiling, predictive analytics, and integrated clinical decision support capabilities. Japanese healthcare providers focus on diagnostic accuracy, consistent clinical performance, and long-term patient benefit through advanced precision medicine implementation.

South Korea Market Split by Country

The South Korean lung cancer diagnostics market shows exceptional growth potential driven by expanding healthcare infrastructure, increasing adoption of precision medicine technologies, and growing demand for advanced molecular diagnostics requiring comprehensive genomic analysis and clinical interpretation capabilities. The market benefits from South Korea's technological leadership in biotechnology and increasing focus on personalized medicine initiatives that drive investment in sophisticated diagnostic platforms meeting international clinical standards.

Korean healthcare organizations increasingly adopt comprehensive molecular profiling systems, artificial intelligence-powered diagnostic tools, and integrated precision medicine protocols to improve cancer care outcomes and treatment efficiency while ensuring regulatory compliance requirements. Growing influence of Korean biotechnology companies and clinical research initiatives supports demand for advanced lung cancer diagnostic solutions that ensure comprehensive functionality while maintaining cost-effectiveness and clinical accessibility. The integration of digital health technologies and telemedicine capabilities creates opportunities for innovative diagnostic platforms with remote consultation and specialized expertise access capabilities.

Competitive Landscape of Lung Cancer Diagnostics Market

The lung cancer diagnostics market is characterized by competition among established diagnostic companies, biotechnology firms, and emerging precision medicine players. Companies are investing in advanced molecular technologies, artificial intelligence integration, comprehensive testing panels, and global market expansion to deliver accurate, accessible, and clinically actionable lung cancer diagnostic solutions. Technology innovation, clinical evidence generation, and regulatory approval strategies are central to strengthening product portfolios and market presence.

F. Hoffmann-La Roche Ltd leads the market with significant global presence, offering comprehensive companion diagnostic solutions with a focus on targeted therapy guidance and precision medicine integration. Thermo Fisher Scientific provides advanced molecular diagnostic platforms with a focus on next-generation sequencing and laboratory automation. Illumina Inc. delivers cutting-edge sequencing technologies with a focus on comprehensive genomic profiling and liquid biopsy applications. Agilent Technologies focuses on molecular pathology solutions that combine high-quality reagents with advanced instrumentation.

Qiagen and Abbott, operating globally, provide comprehensive molecular diagnostic portfolios across multiple testing platforms and clinical applications. Bio-Rad emphasizes quality control and standardization solutions with premium positioning in molecular diagnostics. Neogenomics Laboratories offers specialized cancer diagnostic services with a focus on comprehensive molecular profiling and clinical interpretation. bioMérieux and Myriad Genetics provide targeted diagnostic solutions with a focus on specific biomarker analysis and clinical decision support.

Key Players in the Lung Cancer Diagnostics Market

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific
• Illumina Inc.
• Agilent Technologies
• Qiagen
• Abbott
• Bio-Rad
• Neogenomics Laboratories
• bioMérieux
• Myriad Genetics, Inc.

Scope of the report

Metric	Value
Quantitative Units	USD 14.30 billion to USD 29.47 billion, at a CAGR of 7.50%
Market Definition	The lung cancer diagnostics market encompasses molecular testing platforms, imaging technologies, liquid biopsy assays, and companion diagnostic kits used to detect, classify, and genotype non-small cell and small cell lung cancers, enabling treatment selection through EGFR mutation testing, ALK rearrangement analysis, PD-L1 expression scoring, and comprehensive genomic profiling in laboratory, hospital, and point-of-care settings.
Segmentation	Type (Non-small cell lung cancer), Test (EGFR Mutation test), End Use (Laboratories)
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa
Countries Covered	India, China, USA, Canada, UK, Germany, Japan, and 40 plus countries
Key Companies Profiled	F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Illumina Inc., Agilent Technologies, Qiagen, Abbott, Bio-Rad, Neogenomics Laboratories, bioMérieux, Myriad Genetics, Inc.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified lung cancer diagnostics transaction data, projecting adoption velocity across segments and regions.

Lung Cancer Diagnostics Market by Segments

Type:

• Non-small cell lung cancer
• Small cell lung cancer

Test:

• EGFR Mutation test
• HER2 test
• ALK test
• Angiogenesis Inhibitors
• CA Test
• KRAS Mutation test

End Use:

• Laboratories
• Hospitals
• Others

Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Nordic
  • BENELUX
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia & Pacific
  • Rest of South Asia & Pacific
  • India
  • ASEAN
  • Australia & New Zealand
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Bibliography

• World Health Organization. (2024). Global Cancer Observatory: Lung Cancer Incidence and Mortality Statistics. WHO IARC.
• United States Food and Drug Administration. (2024). List of Cleared or Approved Companion Diagnostic Devices. U.S. FDA.
• European Society for Medical Oncology. (2024). ESMO Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer. ESMO.
• National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. NCCN.
• Centers for Medicare and Medicaid Services. (2024). National Coverage Determination: Next Generation Sequencing for Lung Cancer. CMS.
• Organisation for Economic Co-operation and Development. (2024). OECD Health at a Glance: Cancer Care Quality Indicators. OECD.

This bibliography is provided for reader reference. The full FMI report contains the complete reference list with primary research documentation.

This report addresses

• Market sizing and quantitative forecast metrics detailing precise expenditure on lung cancer diagnostics across major end-use verticals through 2036.
• Segmentation analysis mapping adoption velocity of specific type variants and evaluating structural drivers behind preference shifts.
• Regional deployment intelligence comparing growth trajectories across Asia Pacific, Europe, North America, Latin America, and Middle East and Africa.
• Regulatory compliance assessment analyzing how evolving standards shape procurement specifications across target geographies.
• Competitive posture evaluation tracking consolidation activity, capacity investments, and strategic partnerships among leading participants.
• Strategic guidance defining procurement parameters and supply chain configurations required for lung cancer diagnostics sourcing through the forecast period.
• Supply chain vulnerability analysis identifying concentration risks, raw material dependencies, and logistics bottlenecks.
• Custom data delivery formats encompassing interactive dashboards, raw Excel datasets, and comprehensive PDF narrative reports.